158392-74-6Relevant articles and documents
Discovery of SY-5609: A Selective, Noncovalent Inhibitor of CDK7
Marineau, Jason J.,Hamman, Kristin B.,Hu, Shanhu,Alnemy, Sydney,Mihalich, Janessa,Kabro, Anzhelika,Whitmore, Kenneth Matthew,Winter, Dana K.,Roy, Stephanie,Ciblat, Stephane,Ke, Nan,Savinainen, Anneli,Wilsily, Ashraf,Malojcic, Goran,Zahler, Robert,Schmidt, Darby,Bradley, Michael J.,Waters, Nigel J.,Chuaqui, Claudio
, p. 1458 - 1480 (2021/11/18)
CDK7 has emerged as an exciting target in oncology due to its roles in two important processes that are misregulated in cancer cells: cell cycle and transcription. This report describes the discovery of SY-5609, a highly potent (sub-nM CDK7 Kd) and selective, orally available inhibitor of CDK7 that entered the clinic in 2020 (ClinicalTrials.gov Identifier: NCT04247126). Structure-based design was leveraged to obtain high selectivity (>4000-times the closest off target) and slow off-rate binding kinetics desirable for potent cellular activity. Finally, incorporation of a phosphine oxide as an atypical hydrogen bond acceptor helped provide the required potency and metabolic stability. The development candidate SY-5609 displays potent inhibition of CDK7 in cells and demonstrates strong efficacy in mouse xenograft models when dosed as low as 2 mg/kg.
INHIBITORS OF CYCLIN DEPENDNT KINASE 7 (CDK7)
-
, (2018/02/28)
The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.
Design and synthesis of bicyclic pyrazinone and pyrimidinone amides as potent TF-FVIIa inhibitors
Zhang, Xiaojun,Glunz, Peter W.,Jiang, Wen,Schmitt, Aaron,Newman, Makenzie,Barbera, Frank A.,Bozarth, Jeffery M.,Rendina, Alan R.,Wei, Anzhi,Wen, Xiao,Rossi, Karen A.,Luettgen, Joseph M.,Wong, Pancras C.,Knabb, Robert M.,Wexler, Ruth R.,Scott Priestley
, p. 1604 - 1607 (2013/04/10)
Bicyclic pyrazinone and pyrimidinone amides were designed and synthesized as potent TF-FVIIa inhibitors. SAR demonstrated that the S2 and S3 pockets of FVIIa prefer to bind small, lipophilic groups. An X-ray crystal structure of optimized compound 9b boun